- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03425682
ViBone in Cervical and Lumbar Spine Fusion
July 20, 2021 updated by: Aziyo Biologics, Inc.
A Prospective, Post-Market, Multi-Center Study Evaluating ViBone® in Cervical and Lumbar Spine Fusion
Assess clinical and radiographic outcomes in patients who undergo 1-3 level anterior cervical discectomy fusion (ACDF) or lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, multi-center study to evaluate the clinical and radiographic outcomes of ViBone in patients undergoing ACDF or lumbar interbody fusion.
Data will be gathered for up to 50 subjects undergoing ACDF surgery and up to 50 subjects undergoing lumbar fusion surgery using ViBone.
Total enrollment is expected to be approximately 100 subjects.
The purpose of this study is to assess clinical and radiographic outcomes in patients who undergo 1-3 level ACDF or lumbar interbody fusion surgery using ViBone.
Subjects will be followed for 12 months following surgery.
Study Type
Observational
Enrollment (Actual)
95
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92120
- Spine Institute of San Diego
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Connecticut Neck & Back Specialists, LLC
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
- Anne Arundel Medical Group
-
-
Texas
-
Austin, Texas, United States, 78751
- Orthopedic Specialists of Austin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Male and female patients, 18-80 years of age undergoing 1-3 level anterior cervical discectomy fusion (ACDF), or lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone.
Description
Inclusion Criteria:
- Male or female, 18-80 years of age
- For cervical cases - ACDF surgery at 1, 2, or 3 contiguous levels between C2-C7
- For lumbar cases - lumbar interbody fusion surgery at 1, 2, or 3 contiguous levels between L1-S1
- Patient signed Consent Form with HIPAA Authorization
- Appropriate candidate for surgery
- Patient will adhere to the scheduled follow-up visits and requirements of the protocol including routine patient exams - pre-operative, operative, and at least two post- operative visits (6 and 12 months post-surgery). Pre-operative and post-operative visits include X-ray (required) and CT scan (if available).
Exclusion Criteria:
- Long term use of medications that are known to inhibit fusion or bone metabolism or immune suppressants 6 months prior to surgery (i.e., steroids, chemotherapy, DMARDs, etc.)
- Treatment with radiotherapy
- Acute or chronic systemic or localized spinal infections
- Instability associated with major reconstructive surgery for primary tumors or metastatic malignant tumors of the cervical (for ACDF patients) or lumbar (for TLIF, PLIF, ALIF, or LLIF patients) spine
- Previous pseudoarthrosis at any level of the cervical (for ACDF patients) or lumbar (for
- TLIF, PLIF, ALIF, or LLIF patients) spine
- Nursing mothers or women who are pregnant or plan to become pregnant during the course of the study
- Current or recent history of malignancy or infectious disease. Patients with current or recent history of basal cell carcinoma are eligible.
- Inability to provide informed consent
- Rapid joint disease, bone absorption, osteomalacia, and/or diagnosed osteoporosis (bone density score of ≤-2.5).
- Other medical or surgical conditions which would preclude the potential benefit of surgery, such as congenital abnormalities, immunosuppressive disease, elevation of sedimentation rate unexplained by other diseases, elevation of white blood count (WBC), or marked left shift in the WBC differential count.
- Active local or systemic infection or is undergoing adjunctive treatment for local or systemic infection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cervical Fusion - ACDF
Up to 50 patients undergoing anterior cervical discectomy and fusion (ACDF) using ViBone will be enrolled.
|
Viable Bone Allograft
|
Lumbar Interbody Fusion
Up to 50 patients undergoing lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone will also be enrolled.
|
Viable Bone Allograft
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fusion
Time Frame: 12 months
|
Fusion rates for ViBone from surgical procedure
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ODI
Time Frame: 12 months
|
Oswestry Disability Index (ODI) improvement relative to baseline for lumbar spine fusion
|
12 months
|
NDI
Time Frame: 12 months
|
Neck Disability Index (NDI) improvement relative to baseline for cervical spine fusion
|
12 months
|
VAS
Time Frame: 12 months
|
Visual Analog Scale (VAS) for pain improvement relative to baseline (Pain scale from 0-10, with 0 being No Pain and 10 being Worst Pain)
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 14, 2018
Primary Completion (Actual)
January 15, 2021
Study Completion (Actual)
June 30, 2021
Study Registration Dates
First Submitted
January 29, 2018
First Submitted That Met QC Criteria
February 1, 2018
First Posted (Actual)
February 7, 2018
Study Record Updates
Last Update Posted (Actual)
July 21, 2021
Last Update Submitted That Met QC Criteria
July 20, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP-0001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
ReGelTec, Inc.Not yet recruitingDegenerative Disc Disease (DDD)
Clinical Trials on ViBone
-
Aziyo Biologics, Inc.WithdrawnDegenerative Disc Disease | Spondylolisthesis | Retrolisthesis